Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Specimen Handling 265Magnetic Resonance Spectroscopy 216pembrolizumab 212Carboplatin 173Biopsy 162Cisplatin 155Nivolumab 147Cyclophosphamide 131Paclitaxel 116Radiotherapy 115Gemcitabine 110Bevacizumab 91durvalumab 84Dexamethasone 79Rituximab 74Oxaliplatin 71atezolizumab 67Fluorouracil 66Doxorubicin 65Capecitabine 65Docetaxel 64venetoclax 63Etoposide 63Radiosurgery 58Radiation 57Prednisone 55Ipilimumab 55Cytarabine 55Pemetrexed 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × benralizumab × 90 days × Clear all
NCT04552288 2026-06-01

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
51 enrolled 8 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡